The blood–brain barrier and treatment of lysosomal storage diseases

[1]  A. Vellodi.  Lysosomal storage disorders , 2005, British journal of haematology.

[2]  L. Boon,et al.  Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages. , 2004, American journal of clinical pathology.

[3]  R. Dwek,et al.  Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff disease , 2004, Neurobiology of Disease.

[4]  Anthony H. Futerman,et al.  The cell biology of lysosomal storage disorders , 2004, Nature Reviews Molecular Cell Biology.

[5]  J. M. Aerts,et al.  Inhibition of glycolipid biosynthesis by N-(5-adamantane-1-yl-methoxy-pentyl)-deoxynojirimycin protects against the inflammatory response in hapten-induced colitis. , 2004, International immunopharmacology.

[6]  R. Proia,et al.  Deletion of macrophage-inflammatory protein 1 alpha retards neurodegeneration in Sandhoff disease mice. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[7]  R. Proia,et al.  Blood to brain to the rescue. , 2004, The Journal of clinical investigation.

[8]  R. Lachmann,et al.  Twin pairs showing discordance of phenotype in adult Gaucher's disease. , 2004, QJM : monthly journal of the Association of Physicians.

[9]  G. Andria,et al.  The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: A position statement , 2003, Journal of Inherited Metabolic Disease.

[10]  R. Proia,et al.  Molecular pathophysiology in Tay-Sachs and Sandhoff diseases as revealed by gene expression profiling. , 2002, Human molecular genetics.

[11]  A. Abe,et al.  Agents for the treatment of glycosphingolipid storage disorders. , 2001, Current drug metabolism.

[12]  A. Erikson.  Remaining problems in the management of patients with Gaucher disease , 2001, Journal of Inherited Metabolic Disease.

[13]  T. Cox.  Gaucher disease: understanding the molecular pathogenesis of sphingolipidoses , 2001, Journal of Inherited Metabolic Disease.

[14]  J. Barranger,et al.  Lessons learned from the development of enzyme therapy for Gaucher disease , 2001, Journal of Inherited Metabolic Disease.

[15]  S. Karlsson,et al.  Clinical Gene Therapy in Hematology: Past and Future , 2001, International journal of hematology.

[16]  E. Young,et al.  Pathologic gene expression in Gaucher disease: up-regulation of cysteine proteinases including osteoclastic cathepsin K. , 2000, Blood.

[17]  R. Dwek,et al.  Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis , 2000, The Lancet.

[18]  R. A. Wevers,et al.  The frequency of lysosomal storage diseases in The Netherlands , 1999, Human Genetics.

[19]  S. Gordon,et al.  Mannose Receptor and Its Putative Ligands in Normal Murine Lymphoid and Nonlymphoid Organs: In Situ Expression of Mannose Receptor by Selected Macrophages, Endothelial Cells, Perivascular Microglia, and Mesangial Cells, but not Dendritic Cells , 1999, The Journal of experimental medicine.

[20]  P. Meikle,et al.  Prevalence of lysosomal storage disorders. , 1999, JAMA.

[21]  H. Overkleeft,et al.  Generation of Specific Deoxynojirimycin-type Inhibitors of the Non-lysosomal Glucosylceramidase* , 1998, The Journal of Biological Chemistry.

[22]  C. Hollak,et al.  4 Plasma and metabolic abnormalities in Gaucher's disease , 1997 .

[23]  L. Peltonen.  Molecular background of the Finnish disease heritage. , 1997, Annals of medicine.

[24]  T. Cox,et al.  3 Gaucher's disease: clinical features and natural history , 1997 .

[25]  M. van den Berg,et al.  Synthesis, sorting, and processing into distinct isoforms of human macrophage chitotriosidase. , 1997, European journal of biochemistry.

[26]  V. Gieselmann,et al.  Lysosomal storage diseases. , 1995, Biochimica et biophysica acta.

[27]  O. Ringdén,et al.  Ten years' experience of bone marrow transplantation for Gaucher disease. , 1995, Transplantation.

[28]  K. von Figura,et al.  Biogenesis of lysosomal membranes , 1994, FEBS letters.

[29]  R. Dwek,et al.  N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis. , 1994, The Journal of biological chemistry.

[30]  C. Hollak,et al.  Pathogenesis of lysosomal storage disorders as illustrated by Gaucher disease , 1993, Journal of Inherited Metabolic Disease.

[31]  M. van den Berg,et al.  Role of pH in determining the cell-type-specific residual activity of glucocerebrosidase in type 1 Gaucher disease. , 1993, The Journal of clinical investigation.

[32]  H. Geuze,et al.  Mannose 6-phosphate-independent membrane association of cathepsin D, glucocerebrosidase, and sphingolipid-activating protein in HepG2 cells. , 1991, The Journal of biological chemistry.

[33]  R. Brady,et al.  Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[34]  R. Brady,et al.  Demonstration of a deficiency of glucocerebroside-cleaving enzyme in Gaucher's disease. , 1966, The Journal of clinical investigation.

[35]  A. D. Patrick.  A Deficiency of Glucocerebrosidase in Gaucher's Disease , 1965 .

[36]  R. Wattiaux,et al.  Tissue fractionation studies. 6. Intracellular distribution patterns of enzymes in rat-liver tissue. , 1955, The Biochemical journal.

[37]  Boris Bleijlevens,et al.  Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention. , 2004, Blood.

[38]  R. Dwek,et al.  New therapeutics for the treatment of glycosphingolipid lysosomal storage diseases. , 2003, Advances in experimental medicine and biology.

[39]  R. Schiffmann,et al.  Enzyme Therapy in Type 1 Gaucher Disease: Comparative Efficacy of Mannose-Terminated Glucocerebrosidase from Natural and Recombinant Sources , 1995, Annals of Internal Medicine.

[40]  E. Neufeld,et al.  Lysosomal storage diseases. , 1991, Annual review of biochemistry.

[41]  Charles R.scriver,et al.  The Metabolic basis of inherited disease , 1989 .

[42]  I. Mellman,et al.  The biogenesis of lysosomes. , 1989, Annual review of cell biology.